187 related articles for article (PubMed ID: 35098906)
21. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
Tefferi A; Abdelmagid M; Al-Kali A; Patnaik M; Hogan WJ; Begna K; Gangat N; Orazi A; Chen D; Reichard KK; Pardanani A
Am J Hematol; 2024 Jan; 99(1):21-27. PubMed ID: 37772442
[TBL] [Abstract][Full Text] [Related]
22. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract][Full Text] [Related]
23. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
24. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
25. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
Pardanani A; Lim KH; Lasho TL; Finke C; McClure RF; Li CY; Tefferi A
Blood; 2009 Oct; 114(18):3769-72. PubMed ID: 19713463
[TBL] [Abstract][Full Text] [Related]
26. A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review.
Ibrahim FA; Abdulla MAJ; Soliman D; Al Sabbagh A; Nawaz Z; Akiki SJ; Shwaylia H; Yassin MA
Am J Case Rep; 2020 May; 21():e923354. PubMed ID: 32398637
[TBL] [Abstract][Full Text] [Related]
27. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
[TBL] [Abstract][Full Text] [Related]
28. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.
Quintás-Cardama A; Jain N; Verstovsek S
Cancer; 2011 Dec; 117(24):5439-49. PubMed ID: 21692073
[TBL] [Abstract][Full Text] [Related]
29. An adult patient with systemic mastocytosis and B-acute lymphoblastic leukemia.
Iliakis T; Rougkala N; Diamantopoulos PT; Papadopoulou V; Kalala F; Zervakis K; Giannakopoulou N; Chatzinikolaou P; Levidou G; Lakiotaki E; Korkolopoulou P; Patsouris E; Variami E; Viniou NA
Case Rep Med; 2014; 2014():526129. PubMed ID: 25431599
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
[TBL] [Abstract][Full Text] [Related]
31. Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis.
Radia DH; Moonim MT
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101380. PubMed ID: 36333068
[TBL] [Abstract][Full Text] [Related]
32. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P; Álvarez-Twose I; Pérez-Pons A; Henriques A; Mayado A; García-Montero AC; Sánchez-Muñoz L; González-López O; Matito A; Caldas C; Jara-Acevedo M; Orfao A
Allergy; 2023 May; 78(5):1347-1359. PubMed ID: 36385619
[TBL] [Abstract][Full Text] [Related]
33. [Mastocytosis and eosinophilic leukemia: diagnostics and classification].
Sotlar K; Valent P; Horny HP
Pathologe; 2012 Nov; 33(6):539-52. PubMed ID: 23085697
[TBL] [Abstract][Full Text] [Related]
34. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
35. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
36. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
37. The clinical and pathological panoply of systemic mastocytosis.
Radia DH; Green A; Oni C; Moonim M
Br J Haematol; 2020 Mar; 188(5):623-640. PubMed ID: 31985050
[TBL] [Abstract][Full Text] [Related]
38. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
[TBL] [Abstract][Full Text] [Related]
39. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
[TBL] [Abstract][Full Text] [Related]
40. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD).
Valent P; Arock M; Akin C; Sperr WR; Reiter A; Sotlar K; Hartmann K; George TI; Brockow K; Kluin-Nelemans HC; Gotlib J; Metcalfe DD; Horny HP
Blood; 2010 Aug; 116(5):850-1. PubMed ID: 20688965
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
